Myriad Pharmaceuticals, Inc. Posts Smaller 1Q Loss After Spinoff

AP -- Myriad Pharmaceuticals Inc. on Friday reported a smaller fiscal first-quarter loss on lower research costs after the company was spun off from Myriad Genetics Inc. In its first quarter as an independent company, the research and drug development company lost $10.6 million, or 44 cents per share. That compares to $11.6 million, or 48 cents per share, a year ago. Research revenue dropped to $60,000 from $3.7 million.